Two Sigma Investments LP Sells 77,124 Shares of Repligen Co. (NASDAQ:RGEN)

Two Sigma Investments LP cut its stake in Repligen Co. (NASDAQ:RGEN) by 17.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 359,039 shares of the biotechnology company’s stock after selling 77,124 shares during the period. Two Sigma Investments LP’s holdings in Repligen were worth $51,680,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Ballentine Partners LLC boosted its position in Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares during the period. CIBC Asset Management Inc raised its stake in shares of Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 81 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after acquiring an additional 100 shares in the last quarter. Utah Retirement Systems boosted its holdings in shares of Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 100 shares during the period. Finally, Peapack Gladstone Financial Corp grew its stake in Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company’s stock worth $301,000 after purchasing an additional 103 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at Repligen

In related news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Stock Down 0.2%

Shares of Repligen stock opened at $126.19 on Tuesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.09 billion, a P/E ratio of -247.43, a PEG ratio of 4.54 and a beta of 1.21. The firm’s 50 day moving average price is $132.36 and its 200-day moving average price is $145.11. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen’s revenue was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $0.28 earnings per share. On average, sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of research analyst reports. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Wolfe Research upgraded Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target on the stock in a research note on Tuesday, April 29th. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective for the company. JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Finally, Royal Bank of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.